Boston Trust Walden Corp Acquires 711 Shares of AstraZeneca PLC (NASDAQ:AZN)

Boston Trust Walden Corp increased its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 13.0% in the third quarter, according to its most recent filing with the SEC. The fund owned 6,166 shares of the company’s stock after acquiring an additional 711 shares during the period. Boston Trust Walden Corp’s holdings in AstraZeneca were worth $480,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Price T Rowe Associates Inc. MD increased its holdings in AstraZeneca by 17.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 61,271,974 shares of the company’s stock worth $4,151,177,000 after purchasing an additional 9,002,450 shares during the period. Capital World Investors increased its holdings in AstraZeneca by 0.3% during the 1st quarter. Capital World Investors now owns 9,365,676 shares of the company’s stock worth $634,525,000 after purchasing an additional 29,497 shares during the period. Envestnet Asset Management Inc. increased its holdings in AstraZeneca by 16.7% during the 2nd quarter. Envestnet Asset Management Inc. now owns 3,417,933 shares of the company’s stock worth $266,565,000 after purchasing an additional 488,644 shares during the period. Clearbridge Investments LLC increased its holdings in AstraZeneca by 5.8% during the 2nd quarter. Clearbridge Investments LLC now owns 3,403,748 shares of the company’s stock worth $265,458,000 after purchasing an additional 186,010 shares during the period. Finally, Fayez Sarofim & Co increased its holdings in AstraZeneca by 4.7% during the 1st quarter. Fayez Sarofim & Co now owns 2,990,234 shares of the company’s stock worth $202,588,000 after purchasing an additional 134,784 shares during the period. 20.35% of the stock is owned by institutional investors.

AstraZeneca Trading Down 1.1 %

Shares of NASDAQ:AZN opened at $75.05 on Monday. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68. The business’s fifty day simple moving average is $80.40 and its 200-day simple moving average is $78.59. The company has a market capitalization of $232.70 billion, a PE ratio of 36.26, a P/E/G ratio of 1.39 and a beta of 0.46. The company has a current ratio of 0.89, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Thursday, July 25th. The company reported $0.99 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.01. AstraZeneca had a return on equity of 29.34% and a net margin of 13.11%. The firm had revenue of $12.45 billion for the quarter, compared to the consensus estimate of $12.62 billion. During the same period in the previous year, the business earned $1.08 EPS. The firm’s revenue for the quarter was up 9.1% on a year-over-year basis. As a group, equities research analysts predict that AstraZeneca PLC will post 4.07 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on AZN. Deutsche Bank Aktiengesellschaft downgraded AstraZeneca from a “hold” rating to a “sell” rating in a report on Friday, September 13th. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Finally, TD Cowen lifted their price target on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.